FAT 10, a gene up-regulated in various cancers, is cell-cycle regulated
© Lim et al; licensee BioMed Central Ltd. 2006
Received: 13 July 2006
Accepted: 08 September 2006
Published: 08 September 2006
FAT10 is a member of the ubiquitin-like-modifier family of proteins. Over-expression of the FAT10 gene was observed in the tumors of several epithelial cancers. High FAT10 expression was found to lead to increased chromosome instability via the reduction in the kinetochore localization of MAD2 during the prometaphase stage of the cell-cycle. FAT10 expression was also previously reported to be regulated by cytokines and p53.
Here, we report that FAT10 expression is regulated at the protein and transcript level during cell-cycle with highest expression observed during the S-phase of the cell-cycle. The distal region between -1997 to -975 bp from the transcription start site of the FAT10 promoter may play a role in the repression of FAT10 expression during G2/M phase of the cell-cycle.
FAT10 expression is regulated during cell-cycle.
One of the hallmarks of cancer is the deregulation of cell-cycle controls [1, 2]. The cell-cycle is the timed sequence of events by which a cell duplicates all its components and produces two daughter cells. Successful progression through the cell cycle requires sequential activation of a variety of catalytic subunits called cyclin-dependent kinases (Cdks) that are dependent on the periodic synthesis of cell-cycle specific regulatory subunits known as cyclins . The orderly transitions between the cell cycle phases are regulated by the proteolysis of cyclins; inhibitory phosphorylation of both Cdks and cyclins; as well as by the interaction with inhibitory regulators in a timely fashion . Proteolytic destruction of cyclin proteins occurs through the 26S proteasome pathway, a process whereby each protein is covalently conjugated to an ubiquitin chain at one or more lysine residues, which serves as the signal for targeting the protein to the 26S proteasome for degradation [3, 4]. Defects in the ubiquitin system can lead to a plethora of diseases, including many cancers. For instance, MDM2, an ubiquitin ligase, was found to be amplified in human sarcomas, gliomas, breast carcinomas and leukemias [5–9], probably by deregulating the p53-dependent tumor suppression pathway .
While ubiquitin is a key regulator of the cell cycle, a growing group of related low-molecular-weight proteins known as ubiquitin-like proteins have been identified within the last few years that are implicated in diverse cellular processes. To date, two families of ubiquitin-like proteins are recognized, namely the ubiquitin-like modifiers (UBLs) and ubiquitin-domain proteins (UDPs) . As their family name suggests, they have regions of homology with the 76 amino acids of the ubiquitin protein, but are otherwise unrelated to each other. Like ubiquitin, the UBL family, for example, SUMO/Sentrin and NEDD8/Rub1, function as modifiers by conjugation to other proteins. The UDP proteins, such as RAD23 and Elongin B, on the other hand, are not covalently attached to target proteins although they contain ubiquitin homology domains .
FAT10, also known as diubiquitin, belongs to the UBL class of ubiquitin-like proteins. Initially identified as one of the genes at the major histocompatibility complex locus in human chromosome 6 , the FAT 10 gene encodes an 18 kDa protein containing 165 amino acid residues that shares 29% and 36% identity with ubiquitin at the N- and C-terminus, respectively. Although its function has not been fully elucidated, it has been implicated to play important roles in various cellular processes.
Like ubiquitin , FAT10 also functions as a proteinaceous tag, which when attached to a substrate protein, targets it to the 26S proteasome for degradation . While ubiquitin is recycled from the degraded target proteins, FAT10 has a relatively short half-life and is degraded together with its target . The binding of the NEDD8 ultimate buster 1 long (NUB1L) protein to FAT10 was found to further accelerate the degradation of FAT10 .
Knockout of the FAT10 gene in mice causes minimal phenotypic changes. These mice exhibit increased sensitivity to endotoxin challenge and their lymphocytes are more susceptible to spontaneous apoptotic death .
On the other hand, over-expression of the FAT10 gene was observed in the tumors of several cancers including gastrointestinal and gynecological cancers . High level of the FAT10 protein in cells was recently found to lead to increased mitotic non-dysjunction and chromosome instability . FAT10 was shown to interact with the mitotic checkpoint protein, MAD2, during the mitotic phase of the cell-cycle . An abbreviated mitotic phase and a reduction in the kinetochore localization of the MAD2 protein during the prometaphase stage of the cell-cycle was also observed in cells expressing high levels of the FAT10 protein .
Expression of the FAT10 gene was reported to be up-regulated by cytokines IFN-γ and TNF-α [12, 19, 20]. FAT10 expression was recently shown to be negatively regulated by p53 , which plays important roles in the regulation of the cell-cycle . The abnormally high expression of FAT10 in the tumors of several cancers, coupled with the observation that high FAT10 levels in cells lead to mitotic non-dysjunction and chromosome instability through the reduction of the MAD2 kinetochore localization during the pro-metaphase stage of the cell-cycle; as well as the findings that its expression is positively regulated by TNF-α, a presumptive tumor promoter [14, 23], but negatively regulated by p53, the "guardian-of-the-genome" , together, strongly implicate the important role that FAT10 plays in cell-cycle control and tumorigenesis. Since many genes that are involved in cell-cycle regulation are, themselves, regulated in a cell-cycle dependent fashion [25, 26], in this study, we examine if the expression of the FAT10 gene is also regulated in a cell-cycle dependent manner.
Results and discussion
FAT10 expression in HCT116 human colon carcinoma cells is cell cycle-regulated at the transcript level
The promoter of FAT10 plays a role in the cell-cycle-regulated expression of FAT10
Since FAT10 expression was found to be cell-cycle regulated at the transcript level, we examined the promoter of FAT10 to determine if it plays a role in the cell-cycle regulation of FAT10 expression and to delineate the region of the promoter that may be responsible for the cell-cycle regulation of FAT10 expression. We previously delineated the regions of the FAT10 promoter that mediate promoter activities in Hep3B, HepG2 and KB3-1 cells . In this study, we examined FAT10 promoter activities in HCT116 cells whose FAT10 expression is cell-cycle regulated at both the protein (Fig. 1B) and the transcript levels (Fig. 1C) and which we previously reported that artificial over-expression of the FAT10 gene in these cells results in chromosome instability . As evident in Figure 1E (left panel), maximum FAT10 promoter activity was observed in HCT116 cells when FAT(-1997/+209) and FAT(-975/+209) promoter region was cloned upstream the β-galactosidase reporter and significantly lower promoter activity was found when FAT(-366/+209) and FAT(+1/+209) was cloned upstream the reporter. Hence, the trend of FAT10 promoter activities observed for HCT116 cells were similar to those previously reported for Hep3B, HepG2 and KB3-1 cells although the absolute promoter activity in HCT116 which is p53+ was more similar to p53+HepG2 and KB3-1 cells and approximately 22–30 fold lower than the FAT10 promoter activity in p53- Hep3B cells .
To determine the region of the FAT10 promoter that may mediate cell-cycle regulation, the four constructs carrying different lengths of the FAT10 promoter upstream the β-galactosidase reporter were transfected into HCT116 cells and treated with mimosine, thymidine, or nocodazole to arrest them in G1, S or M phase, respectively, 24 h later. Flow cytometric analyses of DNA were used to confirm the cell-cycle stage of the transfected cells (Fig 1A). Similar to our observation of FAT10 mRNA expression at the different phase of the cell-cycle, when the longest promoter fragment (FAT(-1997/+209)) was cloned upstream the β-galactosidase reporter, highest FAT10 promoter activity was observed in S-phase but not in G1 or G2/M phases (Fig. 1E, right panel). However, when the distal promoter region was deleted to -975 bp from the transcription start site (TSS) (FAT(-975/+209)), the repression of the FAT10 promoter activity at the G2/M phase of the cell-cycle was relieved while its activity at the G1 phase remain low (Fig. 1E, right panel). Hence, the distal promoter region between -1997 and -975 bp from the TSS may play a role in the inhibiting FAT10 expression during the G2/M phase of the cell-cycle.
In light of our earlier observations that over-expression of the FAT10 gene in HCT116 cells will result in the reduction of the kinetochore localization of the important checkpoint MAD2 protein leading to mitotic non-dysjunction and chromosome instability , our current observation that FAT10 expression, through the repression of the FAT10 promoter activity, is kept low during G2/M phase of cell-cycle is notable. It suggests that cells may have evolved to ensure the fidelity of its cell-division by repressing the expression of proteins like FAT10 which might interact and interfere with the functions of important checkpoint proteins like MAD2 during the G2/M phase of the cell-cycle. Repression of the FAT10 gene is observed at two levels, the first general major repression is carried out by the p53 protein  and the second more specific repression is observed at the G2/M phase of the cell-cycle where FAT10 was shown to interact with mitotic checkpoint protein, MAD2. De-regulation of the expression of these proteins like FAT10 would result in the de-regulation of the G2/M cell-cycle phase controls resulting in the abberant distribution of chromosomes during cell-division, hence, leading to tumorigenesis.
Materials and methods
Cell lines and tissue culture
HCT116 (colon carcinoma) cells were purchased from American Type Culture Collection and grown in McCoy's 5A (Sigma) supplemented with 10% fetal calf serum at 37°C in a humidified atmosphere of 5% CO2.
Cell cycle synchronization and flow cytometry
Synchronization of HCT116 cells at the various cell cycle stages was performed according to a protocol described by Su et al . Briefly, cells were initially synchronized to the same cell-cycle phase by incubating them with 3 mM thymidine (Sigma-Aldrich) in McCoy's 5A medium. After 17 h incubation at 37°C, the cells were washed twice with PBS and incubated in normal medium for an additional 12 h at 37°C to release them from the block. The cells were then enriched for G1, S and GM phases by carrying out the following steps: G1 (0.5 mM L-minosine (Sigma-Aldrich) for 15 h); S phase (3 mM thymidine for 16 h); and M phase (100 ng/ml nocodazole (Sigma-Aldrich) for 12 h). Cells were treated with trypsin or 4 mM EDTA and fixed in 1% paraformaldehyde overnight at 4°C for flow cytometry. DNA was stained with 0.01 mg/ml propidium iodide in PBS containing 0.1% Triton X-100 and 0.1 mg/mL RNase A for 1 h at 37°C in the dark. Stained cells were analyzed using the FACScalibur™ flow cytometer (BD Biosciences, Franklin Lakes, NJ).
Western blot analyses was performed on HCT116 cell lysates (7 μg/well) (Lee et al., 2003) using the rabbit anti-FAT10 (Lee et al., 2003), and goat anti-actin (Santa Cruz Biotechnology) primary antibodies and HRP-conjugated anti-mouse or anti-goat IgG secondary antibodies (Pierce Biotechnology). The Western blot membranes were visualized by ECL Advance™ Western blotting detection kit (Amersham Biosciences). Results were quantified through densitometric analysis.
Quantitative real-time RT-PCR analysis
Total cellular RNA was isolated from HCT116 cells using an RNeasy mini-kit (Qiagen). Quantitation of FAT 10 and β-actin transcript levels was performed as previously reported . Briefly, cDNA was synthesized from total RNA using Superscript II reverse transcriptase (Invitrogen) and real-time polymerase chain reaction (PCR) was performed on the cDNA products in a Rotor-Gene 2000 Real-Time Thermal Cycler (Corbett Research) using the QuantiTect™ SYBR® Green PCR Kit (Qiagen) and the following primers: FAT 10 (F: 5'CAATGCTTCCTGCCTCTGTG, R: 5'TGCCTCTTTGCCTCATCACC); β-actin (F: 5'ATGTTTGAGACCTTCACACC, R: AGGTAGTCAGTCAGGTCCCGGCC). The PCR reaction for FAT10 comprise of a denaturation step at 95°C for 15 min followed by 45 cycles of amplification at 95°C for 30 sec, 64°C for 30 sec and 72°C for 30 sec, while β-actin amplification involved an initial denaturation at 95°C for 15 min followed by 40 cycles at 95°C for 30 sec, 55°C for 30 sec and 72°C for 30 sec. SYBR® Green fluorescence was measured after each extension step. Standard curves for FAT 10 and β-actin were generated using serial dilution of plasmids containing the respective cDNAs. The linear range for all the respective gene expression was determined to be between 103 to 108 copies (r2 for FAT10 is 0.9993; and β-actin is 0.992 respectively). FAT 10 expression was normalized against the housekeeping β-actin gene expression. All experiments were performed in triplicate.
Construction of reporter plasmids
A series of different length fragments upstream the TLSS/TSS of the FAT 10 gene (+1/+209, -366/+209, -975/+209 and -1997/+209) were cloned into an expression vector (pFAT10-EGFP) whereby the FAT 10 promoter drives the β-galactosidase (β-gal) reporter gene while the constitutive cytomegalovirus (CMV) promoter drives the enhanced green fluorescent protein (EGFP) reporter gene (Fig. 1D) as described previously . All constructs were sequenced to exclude any PCR errors. Plasmid DNA was prepared using an endotoxin-free Maxi Prep kit (Qiagen).
Transient transfection and β-galactosidase reporter assays
Two hundred thirty thousand HCT116 cells were seeded onto each well of a 6-well plate the day before transfection. Transfection was carried out using Superfect reagent (Qiagen) according to the manufacturer's instructions. After 24-h incubation, cells were enriched for G1, S and M phases by carrying out the steps as described above. Cells were then washed with PBS and solubilized in 1x reporter lysis buffer (Promega) and β-galactosidase activity was determined in a kinetic assay as described previously .
Statistical and computational methods
Statistically significant differences between samples means were determined by single-factor analysis of variance (ANOVA) followed by a post-hoc Tukey's test for multiple pairwise comparisons. P < 0.05 was considered significant.
This work was supported by a grant from the Academic Research Fund (ARF) of the National University of Singapore to Caroline G. Lee, PhD (CGL) and block funding to CG Lee laboratory at the National Cancer Centre, Singapore.
- Malumbres M, Carnero A: Cell cycle deregulation: a common motif in cancer. Prog Cell Cycle Res 2003, 5: 5–18.PubMedGoogle Scholar
- Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100: 57–70. 10.1016/S0092-8674(00)81683-9PubMedView ArticleGoogle Scholar
- McGowan CH: Regulation of the eukaryotic cell cycle. Prog Cell Cycle Res 2003, 5: 1–4.PubMedGoogle Scholar
- Welchman RL, Gordon C, Mayer RJ: Ubiquitin and ubiquitin-like proteins as multifunctional signals. Nat Rev Mol Cell Biol 2005, 6: 599–609. 10.1038/nrm1700PubMedView ArticleGoogle Scholar
- Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP: Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 1993, 53: 2736–2739.PubMedGoogle Scholar
- Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B: Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992, 358: 80–83. 10.1038/358080a0PubMedView ArticleGoogle Scholar
- Bueso-Ramos CE, Yang Y, deLeon E, McCown P, Stass SA, Albitar M: The human MDM-2 oncogene is overexpressed in leukemias. Blood 1993, 82: 2617–2623.PubMedGoogle Scholar
- Ladanyi M, Cha C, Lewis R, Jhanwar SC, Huvos AG, Healey JH: MDM2 gene amplification in metastatic osteosarcoma. Cancer Res 1993, 53: 16–18.PubMedGoogle Scholar
- Sheikh MS, Shao ZM, Hussain A, Fontana JA: The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma. Cancer Res 1993, 53: 3226–3228.PubMedGoogle Scholar
- Momand J, Zambetti GP, Olson DC, George D, Levine AJ: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992, 69: 1237–1245. 10.1016/0092-8674(92)90644-RPubMedView ArticleGoogle Scholar
- Jentsch S, Pyrowolakis G: Ubiquitin and its kin: how close are the family ties? Trends Cell Biol 2000, 10: 335–342. 10.1016/S0962-8924(00)01785-2PubMedView ArticleGoogle Scholar
- Fan W, Cai W, Parimoo S, Schwarz DC, Lennon GG, Weissman SM: Identification of seven new human MHC class I region genes around the HLA-F locus. Immunogenetics 1996, 44: 97–103. 10.1007/s002510050095PubMedView ArticleGoogle Scholar
- Johnson ES, Bartel B, Seufert W, Varshavsky A: Ubiquitin as a degradation signal. Embo J 1992, 11: 497–505.PubMed CentralPubMedGoogle Scholar
- Hipp MS, Kalveram B, Raasi S, Groettrup M, Schmidtke G: FAT10, a ubiquitin-independent signal for proteasomal degradation. Mol Cell Biol 2005, 25: 3483–3491. 10.1128/MCB.25.9.3483-3491.2005PubMed CentralPubMedView ArticleGoogle Scholar
- Hipp MS, Raasi S, Groettrup M, Schmidtke G: NEDD8 ultimate buster-1L interacts with the ubiquitin-like protein FAT10 and accelerates its degradation. J Biol Chem 2004, 279: 16503–16510. 10.1074/jbc.M310114200PubMedView ArticleGoogle Scholar
- Canaan A, Yu X, Booth CJ, Lian J, Lazar I, Gamfi SL, Castille K, Kohya N, Nakayama Y, Liu YC, Eynon E, Flavell R, Weissman SM: FAT10/Diubiquitin-Like Protein-Deficient Mice Exhibit Minimal Phenotypic Differences. Mol Cell Biol 2006, 26: 5180–5189. 10.1128/MCB.00966-05PubMed CentralPubMedView ArticleGoogle Scholar
- Lee CG, Ren J, Cheong IS, Ban KH, Ooi LL, Yong Tan S, Kan A, Nuchprayoon I, Jin R, Lee KH, Choti M, Lee LA: Expression of the FAT10 gene is highly upregulated in hepatocellular carcinoma and other gastrointestinal and gynecological cancers. Oncogene 2003, 22: 2592–2603. 10.1038/sj.onc.1206337PubMedView ArticleGoogle Scholar
- Ren J, Kan A, Leong SH, Ooi LL, Jeang KT, Chong SS, Kon OL, Lee CG: Fat10 plays a role in the regulation of chromosomal stability. J Biol Chem 2006, 281: 11413 -111421. 10.1074/jbc.M507218200PubMedView ArticleGoogle Scholar
- Bates EE, Ravel O, Dieu MC, Ho S, Guret C, Bridon JM, Ait-Yahia S, Briere F, Caux C, Banchereau J, Lebecque S: Identification and analysis of a novel member of the ubiquitin family expressed in dendritic cells and mature B cells. Eur J Immunol 1997, 27: 2471–2477.PubMedView ArticleGoogle Scholar
- Liu YC, Pan J, Zhang C, Fan W, Collinge M, Bender JR, Weissman SM: A MHC-encoded ubiquitin-like protein (FAT10) binds noncovalently to the spindle assembly checkpoint protein MAD2. Proc Natl Acad Sci U S A 1999, 96: 4313–4318. 10.1073/pnas.96.8.4313PubMed CentralPubMedView ArticleGoogle Scholar
- Zhang DW, Jeang KT, Lee CG: p53 negatively regulates the expression of FAT10, a gene upregulated in various cancers. Oncogene 2006, 25: 2318–2327. 10.1038/sj.onc.1209220PubMedView ArticleGoogle Scholar
- Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 1997, 88: 323–331. 10.1016/S0092-8674(00)81871-1PubMedView ArticleGoogle Scholar
- Szlosarek PW, Balkwill FR: Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol 2003, 4: 565–573. 10.1016/S1470-2045(03)01196-3PubMedView ArticleGoogle Scholar
- Lane DP: Cancer. p53, guardian of the genome. Nature 1992, 358: 15–16. 10.1038/358015a0PubMedView ArticleGoogle Scholar
- Dyczkowski J, Vingron M: Comparative analysis of cell cycle regulated genes in eukaryotes. Genome Inform Ser Workshop Genome Inform 2005, 16: 125–131.Google Scholar
- Zwicker J, Muller R: Cell cycle-regulated transcription in mammalian cells. Prog Cell Cycle Res 1995, 1: 91–99.PubMedView ArticleGoogle Scholar
- Su L, Agati JM, Parsons SJ: p190RhoGAP is cell cycle regulated and affects cytokinesis. J Cell Biol 2003, 163: 571–582. 10.1083/jcb.200308007PubMed CentralPubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.